U.S. Department of Health and Human Services
 

 Contact Info

 
Tel: 301-594-8813
Email: eggermant@mail.nih.gov
 

 Select Experience

 
  • Clinical StaffMolecular Disease Branch, NHLBI, NIH1993–Present
  • Senior Research Investigator and Medical OfficerCell and Gene Therapy, U.S. Food and Drug Administration1993–2001
  • Endocrine FellowshipMolecular Disease Branch, NHLBI, NIH1989–1993
  • Medical Staff FellowMolecular Disease Branch, NHLBI, NIH1987–1989

Thomas Eggerman, M.D., Ph.D.

Program Director, Division of Diabetes, Endocrinology, and Metabolic Diseases

Current Responsibilities & Activities

I am a scientific officer for the Clinical Islet Transplantation Consortium (CIT), which is comprised of 13 clinical centers and a coordinating center.  This consortium is interested in supporting multidisciplinary cellular therapy approaches for controlling blood glucose.  Nine protocols have been developed including two pivotal (phase III) studies.  Each study has mechanistic studies designed to help understand the responses seen with each intervention.  Resources include a central web portal for accessing ongoing study information, patient recruitment facts, specimen availability, process details, and statistics.

I am also the program officer for Cystic Fibrosis grants and Centers programs.  The focus is on the non-pulmonary aspects of Cystic Fibrosis.

​Research Programs

Cystic Fibrosis
This program supports both basic and clinical studies on the etiology, molecular pathogenesis, pathophysiology, diagnosis, and treatment of cystic fibrosis and its complications

Cystic Fibrosis Research and Translation Centers
Cystic Fibrosis Research and Translation Centers support both basic and clinical studies aimed at more completely understanding the pathophysiology of cystic fibrosis and developing therapies to treat the disease

Endocrine Pancreas
The Endocrine Pancreas program supports research on the basic biology, development, and function of the endocrine pancreas as well as clinical studies on islet transplantation for the treatment of type 1 diabetes

Genetic Metabolic Disease
This program supports basic and clinical research that addresses the pathophysiology and treatment of inborn errors of metabolism and rare genetic metabolic diseases, including lipodystrophy, maturity onset diabetes of the young (MODY), Primary Hyperoxaluria, systemic amyloidosis and porphyria.

Current Committee Memberships

  • Type 1 Diabetes Working GroupMember
  • Auto-Immunity and Transplantation Working GroupMember